The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's Lymphoma
Abstract
The 2;5 chromosomal translocation occurs in most anaplastic large-cell non-Hodgkin's lymphomas arising from activated T lymphocytes. This rearrangement was shown to fuse the NPM nucleolar phosphoprotein gene on chromosome 5q35 to a previously unidentified protein tyrosine kinase gene, ALK , on chromosome 2p23. In the predicted hybrid protein, the amino terminus of nucleophosmin (NPM) is linked to the catalytic domain of anaplastic lymphoma kinase (ALK). Expressed in the small intestine, testis, and brain but not in normal lymphoid cells, ALK shows greatest sequence similarity to the insulin receptor subfamily of kinases. Unscheduled expression of the truncated ALK may contribute to malignant transformation in these lymphomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Protein Kinase Family: Conserved Features and Deduced Phylogeny of the Catalytic Domains
Hanks, S. K., Quinn, A. M., & Hunter, T. (1988) · Science · doi:10.1126/science.3291115 · Cited by 5,039
Interleukin-2: Inception, Impact, and Implications
Smith, K. A. (1988) · Science · doi:10.1126/science.3131876 · Cited by 2,153
Growth factor signaling by receptor tyrosine kinases
Schlessinger, J., & Ullrich, A. (1992) · Neuron · doi:10.1016/0896-6273(92)90177-f · Cited by 1,430
Major nucleolar proteins shuttle between nucleus and cytoplasm
Borer, R. A., Lehner, C. F., Eppenberger, H. M., & Nigg, E. A. (1989) · Cell · doi:10.1016/0092-8674(89)90241-9 · Cited by 1,114
Dürkop, H., Latza, U., Hummel, M., Eitelbach, F., Seed, B., & Stein, H. (1992) · Cell · doi:10.1016/0092-8674(92)90180-k · Cited by 643
Smith, C. A., Gruss, H.-J., Davis, T., Anderson, D., Farrah, T., Baker, E., Sutherland, G. R., Brannan, C. I., Copeland, N. G., Jenkins, N. A., et al. (1993) · Cell · doi:10.1016/0092-8674(93)90361-s · Cited by 529
T cell antigen receptor activation pathways: The tyrosine kinase connection
Klausner, R. D., & Samelson, L. E. (1991) · Cell · doi:10.1016/0092-8674(91)90310-u · Cited by 428
Chan, W. Y., Liu, Q. R., Borjigin, J., Busch, H., Rennert, O. M., Tease, L. A., & Chan, P. K. (1989) · Biochemistry · doi:10.1021/bi00429a017 · Cited by 270
Interphase and Metaphase Resolution of Different Distances Within the Human Dystrophin Gene
Lawrence, J. B., Singer, R. H., & McNeil, J. A. (1990) · Science · doi:10.1126/science.2203143 · Cited by 257
Brinkman, A., Groffen, C., Kortleve, D. J., Geurts van Kessel, A., & Drop, S. L. (1988) · The EMBO Journal · doi:10.1002/j.1460-2075.1988.tb03087.x · Cited by 247
Cited by
Items 101–144 of 144
Receptor Tyrosine Kinase-Targeted Cancer Therapy
Yamaoka, T., Kusumoto, S., Ando, K., Ohba, M., & Ohmori, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113491 · Cited by 297
Gascoyne, R. D. (2003) · Blood · doi:10.1182/blood-2003-03-0786 · Cited by 297
Cancer Selective Target Degradation by Folate-Caged PROTACs
Liu, J., Chen, H., Liu, Y., Shen, Y., Meng, F., Kaniskan, H. Ü., Jin, J., & Wei, W. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c00451 · Cited by 297
Zhang, X., Zhang, S., Yang, X., Yang, J., Zhou, Q., Yin, L., An, S., Lin, J., Chen, S., Xie, Z., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-188 · Cited by 296
Light-induced control of protein destruction by opto-PROTAC
Liu, J., Chen, H., Ma, L., He, Z., Wang, D., Liu, Y., Lin, Q., Zhang, T., Gray, N., Kaniskan, H. Ü., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay5154 · Cited by 292
Protein tyrosine kinases and cancer
Kolibaba, K. S., & Druker, B. J. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(97)00022-x · Cited by 291
Fujimoto, J., Shiota, M., Iwahara, T., Seki, N., Satoh, H., Mori, S., & Yamamoto, T. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.4181 · Cited by 289
Hernández, L., Pinyol, M., Hernández, S., Beà, S., Pulford, K., Rosenwald, A., Lamant, L., Falini, B., Ott, G., Mason, D. Y., et al. (1999) · Blood · doi:10.1182/blood.v94.9.3265 · Cited by 287
Kazandjian, D., Blumenthal, G. M., Chen, H.-Y., He, K., Patel, M., Justice, R., Keegan, P., & Pazdur, R. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0241 · Cited by 286
Bai, R.-Y., Dieter, P., Peschel, C., Morris, S. W., & Duyster, J. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.12.6951 · Cited by 281
Self-citationCarén, H., Abel, F., Kogner, P., & Martinsson, T. (2008) · Biochemical Journal · doi:10.1042/bj20081834 · Cited by 280
Fusion of ALK to the Ran‐binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor
Ma, Z., Hill, D. A., Collins, M. H., Morris, S. W., Sumegi, J., Zhou, M., Zuppan, C., & Bridge, J. A. (2003) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.10177 · Cited by 280
Self-citationTranslocations involving anaplastic lymphoma kinase (ALK)
Duyster, J., Bai, R.-Y., & Morris, S. W. (2001) · Oncogene · doi:10.1038/sj.onc.1204594 · Cited by 279
Self-citationCrizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase–Positive Lymphoma Patients
Gambacorti Passerini, C., Farina, F., Stasia, A., Redaelli, S., Ceccon, M., Mologni, L., Messa, C., Guerra, L., Giudici, G., Sala, E., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt378 · Cited by 279
Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia
Suzuki, T. (2005) · Blood · doi:10.1182/blood-2005-04-1733 · Cited by 277
Falini, B., Bigerna, B., Fizzotti, M., Pulford, K., Pileri, S. A., Delsol, G., Carbone, A., Paulli, M., Magrini, U., Menestrina, F., et al. (1998) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65629-5 · Cited by 276
ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC)
Du, X., Shao, Y., Qin, H., Tai, Y., & Gao, H. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12613 · Cited by 275
Diagnosis and Molecular Classification of Lung Cancer
Rodriguez-Canales, J., Parra-Cuentas, E., & Wistuba, I. I. (2016) · Cancer Treatment and Research · doi:10.1007/978-3-319-40389-2_2 · Cited by 273
Golding, B., Luu, A., Jones, R., & Viloria-Petit, A. M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0810-4 · Cited by 273
Kelly, L. M., Barila, G., Liu, P., Evdokimova, V. N., Trivedi, S., Panebianco, F., Gandhi, M., Carty, S. E., Hodak, S. P., Luo, J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321937111 · Cited by 271
Nucleophosmin: from structure and function to disease development
Box, J. K., Paquet, N., Adams, M. N., Boucher, D., Bolderson, E., O’Byrne, K. J., & Richard, D. J. (2016) · BMC Molecular Biology · doi:10.1186/s12867-016-0073-9 · Cited by 271
Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer
Lovly, C. M., McDonald, N. T., Chen, H., Ortiz-Cuaran, S., Heukamp, L. C., Yan, Y., Florin, A., Ozretić, L., Lim, D., Wang, L., et al. (2014) · Nature Medicine · doi:10.1038/nm.3667 · Cited by 268
Togashi, Y., Soda, M., Sakata, S., Sugawara, E., Hatano, S., Asaka, R., Nakajima, T., Mano, H., & Takeuchi, K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031323 · Cited by 267
Pathobiology of ALK+ anaplastic large-cell lymphoma
Amin, H. M., & Lai, R. (2007) · Blood · doi:10.1182/blood-2007-04-060715 · Cited by 267
Pallisgaard, N., Hokland, P., Riishøj, D. C., Pedersen, B., & Jørgensen, P. (1998) · Blood · doi:10.1182/blood.v92.2.574 · Cited by 263
Yi, E. S., Boland, J. M., Maleszewski, J. J., Roden, A. C., Oliveira, A. M., Aubry, M.-C., Erickson-Johnson, M. R., Caron, B. L., Li, Y., Tang, H., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318209edb9 · Cited by 263
Zhang, Q., Raghunath, P. N., Xue, L., Majewski, M., Carpentieri, D. F., Odum, N., Morris, S., Skorski, T., & Wasik, M. A. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.1.466 · Cited by 262
Self-citationDifferential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants
Heuckmann, J. M., Balke-Want, H., Malchers, F., Peifer, M., Sos, M. L., Koker, M., Meder, L., Lovly, C. M., Heukamp, L. C., Pao, W., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3260 · Cited by 261
Katayama, R., Lovly, C. M., & Shaw, A. T. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2791 · Cited by 257
Eight-channel iTRAQ Enables Comparison of the Activity of Six Leukemogenic Tyrosine Kinases
Pierce, A., Unwin, R. D., Evans, C. A., Griffiths, S., Carney, L., Zhang, L., Jaworska, E., Lee, C.-F., Blinco, D., Okoniewski, M. J., et al. (2008) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m700251-mcp200 · Cited by 255
Anaplastic Lymphoma Kinase Spares Organ Growth during Nutrient Restriction in Drosophila
Cheng, L. Y., Bailey, A. P., Leevers, S. J., Ragan, T. J., Driscoll, P. C., & Gould, A. P. (2011) · Cell · doi:10.1016/j.cell.2011.06.040 · Cited by 252
NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors
Chiarle, R., Gong, J. Z., Guasparri, I., Pesci, A., Cai, J., Liu, J., Simmons, W. J., Dhall, G., Howes, J., Piva, R., et al. (2003) · Blood · doi:10.1182/blood-2002-05-1343 · Cited by 252
Treating ALK-positive lung cancer—early successes and future challenges
Camidge, D. R., & Doebele, R. C. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.43 · Cited by 236
Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK)
Zhang, C., Han, X.-R., Yang, X., Jiang, B., Liu, J., Xiong, Y., & Jin, J. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.03.071 · Cited by 226
Cancer Vaccines, Adjuvants, and Delivery Systems
Paston, S. J., Brentville, V. A., Symonds, P., & Durrant, L. G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.627932 · Cited by 200
Dependence receptors: a new paradigm in cell signaling and cancer therapy
Goldschneider, D., & Mehlen, P. (2010) · Oncogene · doi:10.1038/onc.2010.13 · Cited by 169
Identification of ALK in thinness
Orthofer, M., Valsesia, A., Mägi, R., Wang, Q.-P., Kaczanowska, J., Kozieradzki, I., Leopoldi, A., Cikes, D., Zopf, L. M., Tretiakov, E. O., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.034 · Cited by 117
Molecular pathogenesis of acute promyelocytic leukaemia and APL variants
Sirulnik, A., Melnick, A., Zelent, A., & Licht, J. D. (2003) · Best Practice & Research Clinical Haematology · doi:10.1016/s1521-6926(03)00062-8 · Cited by 54
Petrazzuolo, A., Perez-Lanzon, M., Martins, I., Liu, P., Kepp, O., Minard-Colin, V., Maiuri, M. C., & Kroemer, G. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-03997-x · Cited by 36
Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells
Amin, A. D., Rajan, S. S., Groysman, M. J., Pongtornpipat, P., & schatz, J. H. (2015) · Biomarkers in Cancer · doi:10.4137/bic.s29326 · Cited by 25
A hypothalamic pathway for Augmentor α -controlled body weight regulation
Ahmed, M., Kaur, N., Cheng, Q., Shanabrough, M., Tretiakov, E. O., Harkany, T., Horvath, T. L., & Schlessinger, J. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2200476119 · Cited by 25
Pearson, A. D., Gaspar, N., Janeway, K., Campbell-Hewson, Q., Lawlor, E. R., Copland, C., Karres, D., Norga, K., Benzaghou, F., Weiner, S., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.06.008 · Cited by 22
Malignant hematopoietic cell lines: in vitro models for the study of anaplastic large-cell lymphoma
Drexler, H. G., & MacLeod, R. A. F. (2004) · Leukemia · doi:10.1038/sj.leu.2403465 · Cited by 16
A Simple, Highly Visual in Vivo Screen for Anaplastic Lymphoma Kinase Inhibitors
Rodrigues, F. S. L. M., Yang, X., Nikaido, M., Liu, Q., & Kelsh, R. N. (2012) · ACS Chemical Biology · doi:10.1021/cb300361a · Cited by 15
Metadata
- Authors
- Morris, S. W., Kirstein, M. N., Valentine, M. B., Dittmer, K. G., Shapiro, D. N., Saltman, D. L., & Look, A. T.
- Venue
- Science
- Published
- 1994-03-04
- Volume
- 263
- Issue
- 5151
- Pages
- 1281-1284
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2038586807
- Cited by
- 2,409
- References
- 17
- FWCI
- 35.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.